Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie ASP3082 u dospělých s dříve léčenými pevnými nádory

13. října 2026 aktualizováno: Astellas Pharma Inc

Studie fáze 1 ASP3082 u účastníků s dříve léčenými lokálně pokročilým nebo metastatickým solidním nádorem s mutací KRAS G12D

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D.

This study will be in 2 parts.

In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2.

In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments.

Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

681

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Bordeaux, Francie
        • Nábor
        • Site FR33002
      • Lyon, Francie
        • Nábor
        • Site FR33001
      • Lyon, Francie
        • Nábor
        • Site FR33005
    • Grenobele
      • La Tronche, Grenobele, Francie
        • Nábor
        • Site FR33003
    • Île-de-France Region
      • Villejuif, Île-de-France Region, Francie
        • Nábor
        • Site FR33004
      • Osaka, Japonsko
        • Nábor
        • Osaka International Cancer Institute
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonsko
        • Nábor
        • Aichi Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japonsko
        • Nábor
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Japonsko
        • Nábor
        • Shikoku Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japonsko
        • Nábor
        • Kurume University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japonsko
        • Nábor
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japonsko
        • Nábor
        • Kanagawa Cancer Center
    • Miyagi
      • Sendai, Miyagi, Japonsko
        • Nábor
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, Japonsko
        • Nábor
        • Niigata Cancer Center Hospital
    • Osaka
      • Hirakata, Osaka, Japonsko
        • Nábor
        • Kansai Medical University Hospital
      • Sayama, Osaka, Japonsko
        • Nábor
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun, Shizuoka, Japonsko
        • Nábor
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, Japonsko
        • Ukončeno
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japonsko
        • Nábor
        • Cancer Institute Hospital of JFCR
    • Yamaguchi
      • Ube, Yamaguchi, Japonsko
        • Nábor
        • Yamaguchi University Hospital
      • Seoul, Jižní Korea
        • Nábor
        • Site KR82006
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Jižní Korea
        • Nábor
        • Site KR82005
      • Seongnam-si, Gyeonggi-do, Jižní Korea
        • Nábor
        • Site KR82002
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Jižní Korea
        • Nábor
        • Site KR82007
    • Seoul
      • Jongno -Gu, Seoul, Jižní Korea
        • Nábor
        • Site KR82001
      • Seodaemun-gu, Seoul, Jižní Korea
        • Nábor
        • Site KR82003
      • Songpa-gu, Seoul, Jižní Korea
        • Nábor
        • Site KR82004
      • San Juan, Portoriko, 00935
        • Nábor
        • PanOncology Trials
    • California
      • Duarte, California, Spojené státy, 91010
        • Nábor
        • City of Hope National Medical Center
      • Santa Monica, California, Spojené státy, 90404
        • Nábor
        • UCLA Santa Monica Hematology Oncology
    • Colorado
      • Denver, Colorado, Spojené státy, 80218
        • Nábor
        • Denver HealthONE Drug Development Unit
    • Connecticut
      • New Haven, Connecticut, Spojené státy, 06520-8028
        • Nábor
        • Smilow Cancer Center at Yale New Haven Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20007
        • Nábor
        • Georgetown University Hospital
    • Florida
      • Gainesville, Florida, Spojené státy, 32610
        • Nábor
        • University of Florida, Davis Cancer Center
      • Lake Mary, Florida, Spojené státy, 32746
        • Ukončeno
        • Florida Cancer Specialist
      • Sarasota, Florida, Spojené státy, 34232-6422
        • Nábor
        • Florida Cancer Specialists & Research Institute Sarasota
    • Kansas
      • Westwood, Kansas, Spojené státy, 66205
        • Nábor
        • University of Kansas Medical Center
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02215
        • Nábor
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Spojené státy, 02215
        • Nábor
        • Dana Farber Cancer Institute
    • Michigan
      • Ypsilanti, Michigan, Spojené státy, 48197
        • Nábor
        • Trinity Health Ann Arbor Hospital
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Nábor
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Spojené státy, 07601
        • Nábor
        • Hackensack University Medical Center
    • New York
      • Buffalo, New York, Spojené státy, 14263
        • Nábor
        • Roswell Park Cancer Institute
      • New York, New York, Spojené státy, 10065
        • Nábor
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Spojené státy, 10032
        • Ukončeno
        • Columbia University - Herbert Irving Comprehensive Cancer Center
      • Rochester, New York, Spojené státy, 14642
        • Nábor
        • University of Rochester Medical Center James P. Wilmot Cancer Center
    • Ohio
      • Cleveland, Ohio, Spojené státy, 44106
        • Nábor
        • Case Western
      • Maumee, Ohio, Spojené státy, 43537
        • Nábor
        • Taylor Cancer Research Center
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Nábor
        • Oregon Health and Science University
    • Tennessee
      • Nashville, Tennessee, Spojené státy, 37232
        • Nábor
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Spojené státy, 37203
        • Ukončeno
        • SCRI Oncology Partners
    • Texas
      • San Antonio, Texas, Spojené státy, 78229
        • Nábor
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Spojené státy, 22031
        • Nábor
        • NEXT Oncology - Virginia Cancer Specialists
    • Wisconsin
      • Madison, Wisconsin, Spojené státy, 53792
        • Nábor
        • University of Wisconsin Hospital
      • Shanghai, Čína
        • Nábor
        • Shanghai Pulmonary Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína
        • Nábor
        • Beijing Cancer Hospital
    • Shanghai Municipality
      • Xuhui District, Shanghai Municipality, Čína
        • Nábor
        • Fudan University Shanghai Cancer Center
      • A Coruña, Španělsko
        • Nábor
        • Site ES34009
      • Barcelona, Španělsko
        • Nábor
        • Site ES34001
      • Barcelona, Španělsko
        • Nábor
        • Site ES34008
      • Barcelona, Španělsko
        • Nábor
        • Site ES34005
      • Madrid, Španělsko
        • Nábor
        • Site ES34004
      • Madrid, Španělsko
        • Nábor
        • Site ES34007
      • Madrid, Španělsko
        • Nábor
        • Site ES34006
      • Málaga, Španělsko
        • Nábor
        • Site ES34002
      • Seville, Španělsko
        • Nábor
        • Site ES34003
      • Valencia, Španělsko
        • Nábor
        • Site ES34010
    • Navarre
      • Pamplona, Navarre, Španělsko
        • Nábor
        • Site ES34011

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented Kirsten rat sarcoma viral oncogene homolog [KRAS] G12D mutation and has received prior standard therapy and the investigator does not see any further clinical benefit from continuing such targeted therapy, or is ineligible to receive standard approved therapies (no limit to the number of prior treatment regimens).

  • For the ASP3082 monotherapy escalation cohorts, participants with solid tumor malignancies are allowed to be enrolled. Participants with other known KRAS G12 mutations will not be eligible for the study

  • For ASP3082 combination therapy with Nab-P+GEM or FOLFIRINOX or NALRIFOX: Participant must have mPDAC that has not been previously treated with chemotherapy. If a participant received (neo)adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the (neo)adjuvant therapy.

  • Participant consents to provide tumor specimen in a tissue block or unstained serial slides or a tumor biopsy (core needle biopsy or excision) obtained after the last interventional treatment, but prior to start of study intervention. Participant also consents to provide a sample for tumor biopsy during the treatment period as indicated in the study protocol. If a participant cannot provide a fresh tissue biopsy sample, the site should consult with the sponsor/study medical monitor.

  • Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

  • Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion.

  • Participant's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of study intervention administration.

  • Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to the start of study intervention administration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids (NOTE: Physiologic replacement dose of hydrocortisone or its equivalent [defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone] is permitted), and not have active radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<= 2 weeks of radiotherapy) to non-central nervous system disease.

  • Participant's adverse events [AEs] (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of study intervention (or prior to staring SoC chemotherapy, for first line (1L) participants receiving Nab-P+GEM FOLFIRINOX or NALIRIFOX.

  • Participant has adequate organ function as indicated by protocol laboratory value parameters (If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 14 days after any blood transfusion.).

  • Female participant is not pregnant, confirmed by pregnancy test and medical evaluation by interview, and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP).
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after study intervention administration.
    • EU only: For combination therapy with carboplatin, follow contraception guidelines from the time of informed consent through at least 7 months after the final dose of carboplatin.
    • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 15 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 14 months after the final dose of cisplatin.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration.

  • Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 6 months after study intervention administration.

  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after study intervention administration.

  • Male participant must not donate sperm during the treatment period and for 3 months after study intervention administration.

  • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 12 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 11 months after the final dose of cisplatin.

  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after study intervention administration.

  • Participant agrees not to participate in another interventional study while receiving study intervention (Participants who are currently in the follow-up period of an interventional clinical trial are allowed).

  • For ASP3082 Combination Therapy with Pembrolizumab (Cohort G), or Platinum-based Chemotherapy + Pemetrexed +/- Pembrolizumab (Cohort H): Participant must have pathologically documented locally advanced or metastatic (unresectable Stage IIIB-IV) non-small cell lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and

    • have received prior platinum-containing chemotherapy (safety lead-in only) or
    • have never received systemic therapy (up to 1 cycle of SoC pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort G and up to 1 cycle of SoC platinum-based chemotherapy ± pembrolizumab [defined as one 21-day cycle of 200 mg] or pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort H is permitted prior to Screening, provided a 21-day washout occurs before C1D1) for locally advanced or metastatic NSCLC with no oncogenic driver mutations. Participants who received adjuvant or neoadjuvant platinum-based chemotherapy and developed recurrent or metastatic disease more than 12 months after completing therapy may be enrolled.

Exclusion Criteria:

  • Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to start of study intervention.
  • Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic, treated CNS metastases are eligible.
  • Participant has leptomeningeal disease as a manifestation of the current malignancy.
  • Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.
  • Participant has a known or suspected hypersensitivity to ASP3082 or any components of the formulation used.
  • Participant with active hepatitis B (including acute hepatitis B virus [HBV] or chronic HBV) or hepatitis C virus [HCV] (ribonucleic acid [RNA] detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing.
  • Participant has a known history of human immunodeficiency virus [HIV] infection. No HIV testing is required unless mandated by a local health authority.
  • Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study intervention, left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO) or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker, or long QT syndrome.
  • Participant has a corrected QT interval (single electrocardiogram [ECG]) using Fridericia's formula (QTcF) > 450 milliseconds (msec) (men) or >470 msec (women) during screening.
  • Participant has received prior treatment with a specific KRAS G12D inhibitor/degrader or pan-RAS inhibitor/degrader targeting KRAS G12D. Participants who received prior treatment with a KRAS G12D inhibitor/degrader are eligible for the ASP3082 combination therapy cohort.
  • Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
  • Participant is expected to require another form of antineoplastic therapy while on study treatment.
  • Participant has any condition which makes the participant unsuitable for study participation (such as psychiatric illness/social situations that would limit compliance with study requirements).
  • Participant has had major surgery within 4 weeks prior to first dose of study intervention.

For ASP3082 Combination Therapy:

  • Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab.
  • History of interstitial lung disease requiring systemic steroid treatment. Note that a participant with resolved pulmonary infections or radiation pneumonitis is eligible.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: ASP3082 Dose Escalation (Monotherapy Part 1)

Participants will receive ASP3082 in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082
Experimentální: ASP3082 Dose Expansion (Monotherapy Part 2)

Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082
Experimentální: ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)

Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Experimentální: ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)

Participants will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Experimentální: ASP3082 China Safety Cohort

Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082
Experimentální: Treatment naive PDAC cohort ASP3082 + FOLFIRINOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with FOLFIRINOX (leucovorin [LV]/fluorouracil [5-FU]/irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Experimentální: Treatment naive PDAC cohort ASP3082 + Nab-Paclitaxel + Gemcitabine

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with Nab-P + GEM (nanoparticle albumin-bound-paclitaxel plus gemcitabine) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Experimentální: ASP3082 + Docetaxel - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with docetaxel in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Experimentální: ASP3082 + Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with pembrolizumab in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Experimentální: ASP3082 + (Cisplatin or Carboplatin) and Pemetrexed +/- Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab in a 21-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Experimentální: Treatment naive PDAC cohort ASP3082 + NALIRIFOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with NALIRIFOX (leucovorin[LV]/fluorouracil[5-FU]/liposomal irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Ostatní jména:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of Dose Limiting Toxicities (DLTs)
Časové okno: Up to 28 Days

A DLT is defined as any event meeting the DLT criteria excluding toxicities clearly related to disease progression or intercurrent illness or standard of care (SoC) regimens as determined by the investigator.

Up to 28 Days
Number of Participants with Adverse Events (AEs)
Časové okno: Up to 48 months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study IP, whether or not considered related to the study investigational product (IP).

Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.

Up to 48 months
Number of Participants with Serious Adverse Events (SAEs)
Časové okno: Up to 48 months

An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.

Up to 48 months
Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
Časové okno: Up to 48 months

Number of participants with potentially clinically significant laboratory values.

Up to 48 months
Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
Časové okno: Up to 48 months

Number of participants with potentially clinically significant ECG values.

Up to 48 months
Number of Participants with vital sign abnormalities and/or adverse events (AEs)
Časové okno: Up to 48 months

Number of participants with potentially clinically significant vital sign values.

Up to 48 months
Number of Participants with physical exam abnormalities and/or adverse events
Časové okno: Up to 48 months

Number of participants with potentially clinically significant physical exam values.

Up to 48 months
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status
Časové okno: Up to 48 months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 48 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Časové okno: Up to 48 months

ORR is defined as the proportion of participants whose best overall response is rated as complete response (CR) or partial response (PR) per RECIST v1.1.

Up to 48 months
Duration of Response (DOR) per RECIST v 1.1
Časové okno: Up to 48 months

DOR is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date of documented radiological disease progression per RECIST v1.1 or death in the absence of progression.

Up to 48 months
Disease Control Rate (DCR) per RECIST v 1.1
Časové okno: Up to 48 months

DCR is defined as the proportion of participants whose best overall response is rated as CR, PR or SD based on RECIST v1.1.

Up to 48 months
Pharmacokinetics (PK) of ASP3082 in plasma: Area under the concentration-time curve (AUC)
Časové okno: Up to 48 months

AUC will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Maximum Concentration (Cmax)
Časové okno: Up to 48 months

Cmax will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)
Časové okno: Up to 48 months

Ctrough will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Time of maximum concentration (tmax)
Časové okno: Up to 48 months

tmax will be recorded from the PK plasma samples collected.

Up to 48 months
Changes in Kirsten rat sarcoma (KRAS) viral oncogene homolog G12D in tumor samples
Časové okno: Up to 48 months

Changes in KRAS G12D in tumor samples will be measured.

Up to 48 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Medical Director, Astellas Pharma Inc

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

8. června 2022

Primární dokončení (Odhadovaný)

31. prosince 2028

Dokončení studie (Odhadovaný)

31. prosince 2028

Termíny zápisu do studia

První předloženo

16. května 2022

První předloženo, které splnilo kritéria kontroly kvality

16. května 2022

První zveřejněno (Aktuální)

19. května 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

14. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 3082-CL-0101
  • jRCT2031220738 (Identifikátor registru: jRCT)
  • CTR20250465 (Identifikátor registru: chinaDrugTrials.org.cn)
  • 2022-501590-39-00 (Identifikátor registru: CTIS (EU))

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Časový rámec sdílení IPD

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Kritéria přístupu pro sdílení IPD

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • CSR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit